FILTER
FILTERED INTERVIEW RESULTS
Rodrigo Gutierrez
CEO, GTM HOLDINGS
GTM Holdings explains how it is experiencing increasing demand for chemicals across the spectrum in Latin America.
Etienne Lepoutre
PRESIDENT – LATIN AMERICA REGION, AIR LIQUIDE
Air Liquide explains how it is managing rapid demand for both industrial and medical gases in Latam.
Peter Staartjes
CEO, ANDINO / ANDIKEM
"Suppliers and end users flexible enough to switch to bulk from containers via the hub and spoke model will gain market share over those who cannot."
Martin Sack
REGIONAL HEAD – AMERICAS, LESCHACO
Leschaco sees a buoyant market for the Latin American chemical trade, but major transport disruptions are a major issue.
Martín Fueyo
DIRECTOR GENERAL, AGRICULTURA NACIONAL S.A. DE C.V. (DRAGÓN)
Agricultura Nacional is relying on its laboratory research and collaboration with its clients for growth in Mexico.
Francisco Rubio
PRESIDENT, KEMIKALS
Kemilkas is a Mexican distributor with a focus on innovation and environmental sustainability.
Luis Eduardo González
PRESIDENT, UMFFAAC
UMFFAAC’s mission is to defend the interests of the crop protection industry in Mexico in terms of its relationship with the authorities and to support food production in a safely manner.
Arturo Hoyo
MANAGING DIRECTOR, NEXEO PLASTICS
Nexeo Plastics describes the market for plastics distribution in Mexico.
Jesús Cabrera
VICE PRESIDENT, GRUPO INFRA
Grupo INFRA discusses the prospects for its business supplying gases in Mexico and beyond.
Eugenio Manzano
EXECUTIVE DIRECTOR, POCHTECA
"Pochteca is expanding operations to reach 10 countries in the Americas as well as expanding services to meet evolving demand."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
